Growth hormone
Ibutamoren
An investigational compound with a documented clinical safety signal.
Human research / safety signal
Also known as: MK-677 · MK677 · ibutamoren mesylate
Practical use
Applying the explained evidence
- Where it fits
- An investigational compound with a documented clinical safety signal.
- Put the information into practice
- A trial in a specific patient population cannot establish safety for healthy physique athletes.
- Outcome versus a marker
- Separate a change in a hormone measurement or body-composition estimate from the outcome you actually care about. Look for direct measurement of function, symptoms and adverse events.
- Keep this limit in view
- Body-composition changes did not translate into demonstrated functional benefits. The study was not large enough to settle long-term safety or predict outcomes in younger athletes.
Overview
Ibutamoren is an oral ghrelin mimetic that stimulates GH and IGF-1. It is often grouped with SARMs in marketing, but the ghrelin/GH pathway is different from androgen-receptor modulation.
Risks and limitations
FDA identifies a potential congestive-heart-failure signal; a trial was stopped early.
How to read this
A trial in a specific patient population cannot establish safety for healthy physique athletes.
Research explained
Randomized older-adult trial
Who was studied
65 healthy adults aged 60–81; primary outcomes assessed after one year.
What was found
Fat-free mass rose about 1.1 kg with ibutamoren versus a 0.5 kg decline with placebo. Strength and function did not improve. Fasting glucose increased and insulin sensitivity decreased; appetite, swelling and muscle discomfort were reported.
What it cannot establish
Body-composition changes did not translate into demonstrated functional benefits. The study was not large enough to settle long-term safety or predict outcomes in younger athletes.
Read the original studyThe key distinction: more lean mass did not mean better function
The older-adult trial separates a biomarker/body-composition response from a practical result: GH/IGF-1 and fat-free mass changed, but strength and function did not improve. This is why a “muscle-building” headline can overstate what the experiment actually demonstrated.
Supporting sourceMetabolic tradeoffs matter
The same trial reported higher fasting glucose and reduced insulin sensitivity. A favorable change in one body-composition variable does not cancel an unfavorable metabolic change. Appetite and fluid-related effects also complicate interpretation of weight changes.
Supporting sourceWhy the heart-failure signal stays visible
FDA identifies a trial in people recovering from hip fracture that stopped early over a potential congestive-heart-failure signal. That does not calculate the risk in a young athlete, but it is a real reason not to describe the compound as proven safe.
Supporting sourceCommon questions
Is MK-677 a SARM?
No. It acts through a ghrelin-related pathway and was studied for GH/IGF-1 responses. Marketing alongside SARMs does not make it an androgen-receptor modulator.
SourceLearn with Avery
Sources
Sources checked 2026-09-28.
General education; not a personal treatment plan.